AbCellera Biologics Inc. (ABCL)

Market Cap	3.64B
Revenue (ttm)	603.19M
Net Income (ttm)	248.36M
Shares Out	285.32M
EPS (ttm)	0.78
PE Ratio	15.27
Forward PE	27.47
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,552,344
Open	12.65
Previous Close	12.71
Day's Range	11.85 - 12.72
52-Week Range	5.42 - 15.9
Beta	n/a
Analysts	Buy
Price Target	29.92 (+151.2%)
Earnings Date	Nov 8, 2022

About ABCL

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquart...

• Industry: Biotechnology
• IPO Date: Dec 11, 2020
• Employees: 475
• Stock Exchange: NASDAQ
• Ticker Symbol: ABCL

Financial Performance

In 2021, ABCL's revenue was $375.20 million, an increase of 60.92% compared to the previous year's $233.16 million. Earnings were $153.46 million, an increase of 29.05%.

Analyst Forecast

According to 15 analysts, the average rating for ABCL stock is "Buy." The 12-month stock price forecast is 29.92, which is an increase of 151.22% from the latest price.

Price Target

$29.92

(151.22% upside)

Analyst Consensus: Buy